Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650637 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT00650637: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00650637 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 17 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00650637, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.
Interventions
- DRUG lamivudine
- DRUG Calcium Carbonate
- DRUG loperamide
- DRUG nelfinavir
- OTHER Calcium carbonate not administered
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
Why NCT00650637 stopped before completion
NCT00650637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which lamivudine is the first listed.
NCT00650637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00650637 about?
NCT00650637 is a clinical study titled "A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea". The purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.
What is the current status of trial NCT00650637?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2003-01. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00650637?
The interventions under investigation include: lamivudine (DRUG), Calcium Carbonate (DRUG), loperamide (DRUG), nelfinavir (DRUG), Calcium carbonate not administered (OTHER).
Who is sponsoring clinical trial NCT00650637?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00650637's enrollment target sits among peer trials
17 1971st of 2000 higher than 27 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia